|
You’ve read about it in the media. Europeans have experienced its health benefits for two decades. Now consumers in the United States have access to a nutrient with groundbreaking potential.
SAMe, a natural compound formed in our bodies from the amino acid methionine, has stirred excitement due to its wide-ranging health effects. SAMe plays a critical role in cartilage formation. Clinical studies have demonstrated that SAMe helps support joint comfort, function, and mobility in the spine, hips, and knees.
SAMe has also been found to support a positive outlook due to its affect on the synthesis and activation of proteins, such as mood-boosting neurotransmitters. |
A Multipurpose Nutrient
SAMe, or S-adenosyl L-methionine, is formed when our bodies combine the amino acid L-methionine with ATP, the primary energy-carrying molecule in our cells. This nutrient is present in every living cell. Because SAMe is involved in so many vital processes, it is important that our bodies produce sufficient amounts. However, SAMe levels tend to decline with age, and can also be affected by dietary imbalances.
To produce adequate amounts, we need to consume not only methionine-containing protein foods, but also foods rich in vitamins B-6, B-12 and folic acid, which are needed to ensure the synthesis of SAMe.
Additionally, SAMe is a highly unstable molecule; therefore, a lot of scientific research was needed to make it available as a supplement. Source Naturals has studied the research and offers this vital nutrient in a form your body can use.
Methylation is the Key
SAMe is known as a “methyl donor.” This means that it works by giving up a piece of itself (a methyl group consisting of one carbon and three hydrogen atoms) to other molecules. This methylation process affects the synthesis, activation, and metabolism of various hormones, neurotransmitters, phospholipids, nucleic acids, proteins, and other biological molecules.
Methylation plays a part in many critical functions, including the maintenance of cell membranes, the removal of toxic substances from the body, and the production of mood-boosting neurotransmitters,
such as dopamine and serotonin.
Effective Joint Support
SAMe has been used in Europe for two decades for joint support with positive results. Studies have shown that the breakdown of SAMe generates sulfate groups that help maintain joint cartilage. SAMe also helps to form proteoglycans, which are used to renew the matrix of cartilage.
Promotes Mental Well-Being
Studies also show that SAMe helps support a positive outlook. Although the mechanism by which SAMe promotes mental well-being is not known, we do know it is able to cross the blood-brain barrier, where it affects the production of mood-boosting neurotransmitters.
SAMe and Fibromyalgia
Preliminary studies have suggested that SAMe may be helpful for those with fibromyalgia. A small double-blind study evaluated the effect of S-adenosylmethionine (SAMe) or placebo in 17 people with fibromyalgia, 11 of whom had depression. The number of tender points decreased after SAMe but not placebo. Depression, as assessed by two rating scales, improved after SAMe but not placebo.
In another double-blind study, 44 people with fibromyalgia took 800 mg of S-adenosylmethionine a day or placebo. After 6 weeks, there were statistically significant improvements in pain, fatigue, morning stiffness, mood, and clinical disease activity. Tender point score, muscle strength, and mood (evaluated by the Beck Depression Inventory) were not significantly better with SAMe than placebo.
Clinically Researched Potency
Source Naturals SAMe is offered in the clinically researched potency of 400 mg per suggested daily use (one tablet). The tablets are enteric coated and blister packed to prevent breakdown and inactivation of ingredients.
Supplement Facts
Capsules per Container: 30 Tablets, 400 mg
Serving Size: One (1) Tablet
Servings per Container: 30
Suggested Use: One tablet, one to three times daily. Take tablets on an empty stomach.
Supplement Facts for 400 mg Tablet
Serving Size: 1 tablet(s) |
| |
Amount |
%DV |
| SAMe (S-adenosyl-L-methionine) |
400 mg |
† |
| from 800 mg of SAMe disulfate tosylate |
|
|
|
� Daily Value not established.
Other Ingredients: Cellulose, mannitol, hydroxypropyl methylcellulose pthalate, citric acid, sodium starch glycolate, glyceryl triacetate, modified cellulose gum, stearic acid, colloidal silicon dioxide, titanium dioxide and yellow ochre.
Suitable for vegetarians. Contains no yeast, dairy, egg, gluten, soy or wheat. Contains no sugar, salt, preservatives, or artificial flavor or fragrance.
Warning: If you are pregnant or breastfeeding consult your physician before using this product. Sufferers of bipolar disorder shouldn’t use SAMe unless under medical supervision. Those taking anti-depressant medications should confer with their physician before taking SAMe in place of or in addition to those medications and they should continue to be monitored. Some caution is advised in those who have cancer due to the methylating properties of SAMe. In a small percentage of people this product may cause nausea which tends to subside with long-term use. Do not use if either tamper-evident seal is broken or missing. Keep out of the reach of children.
Manufactured by Source Naturals
|
SAMe
Supports Joint Comfort and a Positive Mood
by Source Naturals
30 Tablets, 400 mg
$27.95 - Discount Price (Retail Price $42.98 - Save 35%)
|
References
Berger, R. et al. 1987. “A New Medical Approach....” The American Journal of Medicine; 83(5A): 84-88.
Carney, MWP et al. 1987. “S-adenosylmethionine....”The American Journal of Medicine;
83(5A): 104-106.
Konig, B. 1987. “A long-term (two years) clinical trial of oral S-adenosylmethionine....” The
American Journal of Medicine; 83(5A): 89-94.
Stramentinoli, G. 1987. “Pharmacological aspects of S-adenosylmethionine.” The American Journal of Medicine; 83(5A):35-42
Jacobsen S, Danneskiold-Samsoe B, Andersen RB. Oral S-adenosylmethionine in primary fibromyalgia. Double-blind clinical evaluation. Scand J Rheumatol. 20.4 (1991): 294-302.
Tavoni A, Vitali C, Bombardieri S, Pasero G. Evaluation of S-adenosylmethionine in primary fibromyalgia. A double-blind crossover study. Am J Med. 83.5A (1987): 107-110.
Volkmann H, Norregaard J, Jacobsen S, Danneskiold-Samsoe B, Knoke G, Nehrdich D. Double-blind, placebo-controlled cross-over study of intravenous S-adenosyl-L-methionine in patients with fibromyalgia. Scand J Rheumatol. 26.3 (1997): 206-211.
|
